New Company

[Anonymous]

Is it true Pfizer buying Amarin Corp. for its Omega 3 fish oil? To replace Lipitor

 

[Anonymous]

doubt any omega 3 pill will ever replace the 13 billions $ pill!!!!

 

[Anonymous]

Yes it is absolutly true and you heard it first here on cafepharma, the reliable source of information for the rep that wants to stay informed. Buy their stock now, as much as you can, and you will be in on the ground floor!

 

[Anonymous]

Fact: Omega-3 is big business. Audits show $2.5 billion was sold in the US last year.

Fact: Amarin has an FDA action date in June for an especially pure form of Omega-3 that avoids certain contaminants found in other "fish oil" products

Fact: Leadership of Amarin has made no secret of their being receptive to being boght after the product is approved

Draw your own conclusions...

 

[Anonymous]

Can Pfizer create anything new...from Pfizer?

Or must everything be purchased.

Quite a shame that there is no innovation...solely relying upon others.

The Pfizer pflame sure is burning dim.

 

[Anonymous]

We did this to ourselves

Can Pfizer create anything new...from Pfizer?

Or must everything be purchased.

Quite a shame that there is no innovation...solely relying upon others.

The Pfizer pflame sure is burning dim.

Because all our R&D was allowed to focus on was the next Lipitor or Viagra. Thanks to the brilliant people at the helm, we have nothing to pin our hopes on BECAUSE WE WERE TOO DUMB TO REALIZE THAT THE ODDS OF PFINDING ANOTHER VIAGRA OR LIPITOR WITH LITTLE GENERIC COMPETITION ARE EXTREMELY SMALL
(Sorry for yelling)

 

[Anonymous]

Fact: Omega-3 is big business. Audits show $2.5 billion was sold in the US last year.

Fact: Amarin has an FDA action date in June for an especially pure form of Omega-3 that avoids certain contaminants found in other "fish oil" products

Fact: Leadership of Amarin has made no secret of their being receptive to being boght after the product is approved

Draw your own conclusions...

FACT: AMRN PDUFA is late July, not June

 

[Anonymous]

Amarin is just a joke, they only have a 30 year old Japanese product called "EPA-E"!

Can't compete with Lovaza (or generic Lovaza soon on the market), it has no value for Pfizer or anyone else.

 

[Anonymous]

Your comments show how misinformed (and/or stupid) you are about Amarin and their lead product.

 

[Anonymous]

"Lead" product?

They only have ONE product.

And that is a product developed in Japan decades ago and it IS called "EPA-E".

Pfizer can start buying that tomorrow an run a couple of trials, anyone can do that.

But why don't they?

BECAUSE you can't make MONEY on it.

Why?

Because of the incredibly expensive production cost in comparison with Lovaza AND the fact that you can't protect it.

So yes, "AMR-101" is a JOKE.

 

[Anonymous]

AMR101 is patent protected (announced today). Read through the info contained in the link to educate yourself on the product. It will be a blockbuster as it is superior to Lovaza (discussed in the link).

http://www.amarincorp.com/products/pipeline.html

You might want to do some more reading on AMRN because it is one heck of a stock to own right now. It's projected to double in price on or before AMR101's PDUFA date in late July.

 

[Anonymous]

Hey genius, you can't patent a decades old product other people make for you.

And everyone knows that Lovaza is superior, that is common knowledge, even in Japan.

Takeda are actually launching Lovaza in Japan next year!

Just took a look at the price of Amarin and the company is priced at almost 2 billion!!

And they have NOTHING, I repeat, ANYONE can buy "EPA-E" tomorrow from several producers!

This is REALLY insane I tell you, if you actually own that stock you should get the hell out of dodge ASAP!!

 

[Anonymous]

http://pharmalive.com/News/index.cfm?articleid=842068

Ahead of the Bell: Patent Defense May Aid Amarin

From Associated Press (May 30, 2012)

Another pharmaceutical company’s successful defense of a U.S. patent on a blood treatment drug pushed shares of Amarin higher in premarket trading Wednesday as it bodes well for one of its products, which also faces potential challenges from generics.

The Norwegian drug developer Pronova said Tuesday that a federal court has upheld the validity of some patents protecting its heart medication Lovaza from generic competition in the U.S. market. Lovaza is sold in the United States and Puerto Rico by British pharmaceutical giant GlaxoSmithKline PLC.

Pronova said the U.S. District Court for the District of Delaware found that its patent claims were valid and enforceable and would be infringed by generic drug makers Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Inc. One of the patents expires in March 2013 and another in April 2017.

Pronova had filed patent infringement litigation against Teva and Par in April 2009.

The successful patent defense will relieve Amarin investor worries that its potential treatment, AMR101, would face cheaper generic competition immediately after it launched, Jefferies analyst Thomas Wei said in a research note.

AMR101 is designed to treat high levels of triglycerides, or fats in the blood. The Food and Drug Administration is scheduled to make a decision on the drug by July 26. If approved, it will be the first marketed product for Amarin, which is based in Ireland.

The ruling also improves the likelihood that an AMR101 patent would prevail if challenged and reduces the chance that generic drug makers challenge that patent, Citi analyst John Boris said in a separate note.

Boris has said sales of AMR101 could reach surpass $2 billion annually and it could become the leading triglyceride-lowering drug, surpassing Lovaza and Abbott Laboratories Inc.’s drugs Tricor and Trilipix.

Shares of Amarin Corp. rose 1.5 percent, or 18 cents, to $12.45 before the market opened, after spiking 6 percent Tuesday."

 

[Anonymous]

http://investor.amarincorp.com/releasedetail.cfm?releaseid=677533

AMARIN ANNOUNCES U.S. PATENT ISSUANCE FOR AMR101
Issuance for '598 Application: "EPA Without DHA in a Capsule"
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's AMR101 based on U.S. Patent Application Serial No. 12/052,598, also known as the*EPA*with no DHA in a capsule application.*Amarin announced on March 20, 2012, the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,188,146, is titled "Highly Purified Ethyl EPA and Other EPA Derivatives."

"The issuance of this patent is an important step forward in strengthening Amarin's position as a leader in the next generation of lipid management therapy," said Joseph Zakrzewski, Amarin's Chairman and CEO. "Amarin's*plan is to protect the commercial potential of AMR101 to 2030 and beyond. This plan consists of pursuing additional patent protection, seeking regulatory exclusivity, maintaining trade secrets and taking advantage of manufacturing barriers to entry."

This patent is part of an expanding patent portfolio for Amarin. Amarin is currently prosecuting more than 25 patent applications in the United States relating to AMR101.

About AMR101

AMR101 (icosapent ethyl) is an ultra pure omega-3 fatty acid, comprising not less than 96% EPA (icosapent ethyl), that Amarin is developing as a treatment for patients with very high triglyceride levels (≥500 mg/dL), and for patients with high triglyceride levels (≥200 and < 500mg/dL) who are also on statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C, levels (which we refer to as mixed dyslipidemia). The efficacy and safety of AMR101 were studied in two Phase 3 clinical trials, the MARINE trial, which studied patients with very high triglyceride levels, and the ANCHOR trial, which studied patients with high triglyceride levels who were also on statin therapy for elevated LDL-C levels. These two Phase 3 clinical trials showed favorable results in triglyceride reduction compared to placebo in the studied patient populations. Reduction in triglyceride levels was achieved without a statistically significant increase in LDL-C levels, and in the 4 gram AMR101 ANCHOR results, with a statistically significant decrease in LDL-C levels. These trials also showed favorable results, particularly with the 4 gram dose of AMR101, in other important lipid and inflammation biomarkers, including Apo-B, non-HDL-C, Total-Cholesterol, VLDL-C, Lp-PLA2, and hs-CRP. In these trials, AMR101 exhibited a safety profile comparable to placebo. In December 2011, Amarin commenced patient dosing in a cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with EPA — Intervention Trial), that is designed to evaluate the efficacy of AMR101 in reducing major cardiovascular events in a high risk patient population on statin therapy.

 

[Anonymous]

News for 'AMRN' - (Amarin drug gets 1st patent)


GROTON, May 30, 2012 (The Day - McClatchy-Tribune Information Services via
COMTEX) -- Amarin Corp. plc, the Irish drug company with
research-and-development headquarters on Thames Street, said Tuesday that it has
received the first patent for its lead heart drug, currently known as AMR101.

AMR101, which will be marketed under a different name if the U.S. Food and Drug
Administation gives its stamp of approval later this year, has been shown to
control the buildup of fat in the blood, a key factor in heart disease. It is
expected to be an improvement over a blockbuster GlaxoSmithKline drug known as
Lovaza that also controls fat buildup.

Amarin Chairman and Chief Executive Officer Joseph Zakrzewski called AMR101's
patent approval "an important step forward" for the company.

The patent, known by its number 8,188,146 and titled "Highly Purified Ethyl EPA
and Other EPA Derivatives," settles once and for all the question over whether
Amarin's promising heart drug would pass muster with the U.S. Patent and
Trademark Office. The company's stock, which surged near the $20 level after a
series of encouraging data was released during 2010-2011, had been battered by
late last year, falling to about a third of its high.

By Tuesday, however, the stock had regained much of its luster as investors came
to expect patent approval, and Amarin's stock initially fell on news of the U.S.
approval. But an announcement later in the day that Teva Pharmaceuticals and Par
Pharma had lost their bid to sell a generic form of Lovaza sent Amarin's shares
into a steep incline, with the price settling $12.27 a share, up more than 6
percent.

The patent for AMR101, which is a highly purified Omega-3 fish oil, protects
Amarin's intellectual property through 2030. It also could remove any doubts as
to the company's suitability as a buyout candidate or partner, though Amarin
officials have not yet tipped their hand on which option they would prefer.

Amarin promised, however, that it would continue seeking other avenues of patent
protection and said that it currently has more than 25 applications pending in
the United States to block potential rivals from cashing in on copycat versions
of AMR101.

l.howard@theday.com



___ (c)2012 The Day (New London, Conn.) Visit The Day (New London, Conn.) at

www.theday.com Distributed by MCT Information Services

Lee Howard


Copyright (C) 2012, The Day, New London, Conn.

-0-




SUBJECT CODE: ****NL



Source: Comtex Wall Street News

Compliments of Scottrade.com